组蛋白脱乙酰化酶抑制剂对失血性和感染性休克早期救治作用的研究进展  

Recent developments in the early treatments of hemorrhagic shock and septic shock utilizing histone deacetylase inhibitors

作　　者：张彦圆[1] 耿智隆[1] 

机构地区：[1]兰州军区兰州总医院麻醉科,730050

出　　处：《国际麻醉学与复苏杂志》2013年第1期66-69,共4页International Journal of Anesthesiology and Resuscitation

基　　金：基金项目：全军“十一五”面上基金课题（06MA083）

摘　　要：背景休克早期的药物救治，一直普遍受到关注，近来组蛋白脱乙酰化酶抑制剂（histone deacetylabe inhibitors，HDACI）因其突出的抗休克作用成为国际研究热点。目的回顾目前HDACI的临床应用方向和分类，讨论其作为抗失血性休克和感染性休克药物的突出优势以及作用机制。内容HDACI可通过抗细胞凋亡等多种途径，提高细胞对休克所致缺血，缺氧环境的耐受能力，改善失血性休克和感染性休克动物模型的预后。趋向HDACI已成为抗失血性休克和感染性休克研究的新方向，是提高休克早期生存率的新策略，也为休克的治疗提供了药物配合液体复苏的新途径。Backgroud Histone deacetylase inhibitors（HDACI） received attention because of its outstanding protection role in the early pharmacological resuscitation of shock. Objective To review the clinical application and classification of HDACI, and discuss its advantages and mechanisms as a drug for hemorrhagic shock and septic shock. Content HDACI is promising to early survival of shock through its anti-apoptosis effect and many other mechanisms, offers considerable protection in the hemorrhagic shock and septic shock model. Trend HDACI is a new strategy for approving early survival, at the same time provide （provides） potential new clinical applications of shock in the future.

关 键 词：组蛋白脱乙酰化酶抑制剂 失血性休克 感染性休克 

分 类 号：R459.7[医药卫生—急诊医学]